Etoposide-Loaded PLGA and PCL Nanoparticles I: Preparation and Effect of Formulation Variables

REFERENCES

• I. Bala, S. Hariharan, and M. N. Kumar. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier. Syst. 21:387–422.
   PubMed Web of Science ®Google Scholar
• I. Brigger, C. Dubernet, and P. Couvreur. (2002). Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 54:631–651.
   PubMed Web of Science ®Google Scholar
• A. Budhian, S. J. Siegel, and K. I. Winey. (2005). Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J. Microencapsul. 22:773–785.
   PubMed Web of Science ®Google Scholar
• A. Budhian, S. J. Siegel, and K. I. Winey. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int. J. Pharm. 336:367–375.
   PubMed Web of Science ®Google Scholar
• M. Chorny, I. Fishbein, H. D. Danenberg, and G. Golomb. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 83:389–400.
   PubMed Web of Science ®Google Scholar
• M. D. Coffin, and J. W. McGinity. (1992). Biodegradable pseudolatexes: the chemical stability of poly (D,L-lactide) and poly (ε -caprolactone) nanoparticles in aqueous media. Pharm. Res. 9:200–205.
   PubMed Web of Science ®Google Scholar
• M. S. Espuelas, P. Legrand, J. M. Irache, C. Gamazo, A. M. Orecchioni, J. P. Devissaguet, and P. Ygartua. (1997). Poly (ε -caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158:19–27.
   Web of Science ®Google Scholar
• S.-S. Feng, and G. Huang. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J. Control. Release 71:53–69.
   PubMed Web of Science ®Google Scholar
• H. Fessi, F. Puisieux, J. P. Devissaguet, N. Ammoury, and S. Benita. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55:R1–R4.
   Web of Science ®Google Scholar
• C. Gomez-Gaete, N. Tsapis, M. Besnard, A. Bochot, and E. Fattal. (2007). Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 331:153–159.
   PubMed Web of Science ®Google Scholar
• W. He, S. W. Horn, and M. D. Hussain. (2007). Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int. J. Pharm. 334:173–178.
   PubMed Web of Science ®Google Scholar
• M. N. Kumar, and N. Kumar. (2001). Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Dev. Ind. Pharm. 27:1–30.
   PubMed Web of Science ®Google Scholar
• H.-Y. Kwon, J.-Y. Lee, S.-W. Choi, Y. Jang, and J.-H. Kim. (2001). Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf. A: Physicochem. Eng. Aspects 182:123–130.
   Web of Science ®Google Scholar
• A. Lamprecht, N. Ubrich, M. Hombreiro Perez, C. M. Lehr, M. Hoffman, and P. Maincent. (2000). Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int. J. Pharm. 196:177–182.
   PubMed Web of Science ®Google Scholar
• D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman, and P. Maincent. (1996). Stability study of nanoparticles of poly (ε -caprolactone), poly (D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials 17:2191–2197.
   PubMed Web of Science ®Google Scholar
• J. C. Leroux, E. Allemann, E. Doelker, and R. Gurny. (1995). New approach for the preparation of nanoparticles by an emulsification diffusion method. Eur. J. Pharm. Biopharm. 41:14–18.
   Web of Science ®Google Scholar
• M. Y. Levy, and S. Benita. (1990). Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int. J. Pharm. 66:29–37.
   Web of Science ®Google Scholar
• H. Murakami, M. Kobayashi, H. Takeuchi, and Y. Kawashima. (1999). Preparation of poly (dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187:143–152.
   PubMed Web of Science ®Google Scholar
• P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, S. Marsoni, and R. E. Wittes. (1985). Etoposide (VP-16–213). Current status of an active anticancer drug. N. Engl. J. Med. 312:692–700.
   PubMed Web of Science ®Google Scholar
• Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto. (1988). A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull. 36:1095–1103.
   PubMed Web of Science ®Google Scholar
• L. Peltonen, P. Koistinen, M. Karjalainen, A. Hakkinen, and J. Hirvonen. (2002). The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight poly(l)lactide. AAPS Pharm. Sci. Tech. 3:E32.
   PubMedGoogle Scholar
• D. Quintanar-Guerrero, H. Fessi, E. Allemann, and E. Doelker. (1996). Influence of stabilizing agents and preparative variables on the formation of poly (d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. Int. J. Pharm. 143:133–141.
   Web of Science ®Google Scholar
• J. C. Shah, J. R. Chen, and D. Chow. (1989). Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 6:408–412.
   PubMed Web of Science ®Google Scholar
• K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70:1–20.
   PubMed Web of Science ®Google Scholar
• K. Yamaoka, T. Nakagawa, and T. Uno. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165–175.
   PubMedGoogle Scholar